If I'm reading this right (HIGHLY questionable), here's my

New Post Public Reply Private Reply Replies (1) Message Board
homerbedloe
503
If I'm reading this right (HIGHLY questionable), here's my take on the latest S1:

1 million preferred at $33/share, bringing $33 million to GNBT. Those shares then trade at market price between investors, so no impact on GNBT common other than there is a cash value to GNBT, so ideally the share price goes up.

For every 10 of the 1 million shares, the holder is issued a warrant for 1 share of GNBT common stock, with an exercisable price of $15/share. So there are 100,000 chances (1 million/10) to redeem up to 100,000 common shares at $15/share. So if each warrant is exercised (ie, GNBT stock price exceeds $15 per share within the next 2 years), GNBT could potentially raise $1.5 million (100,000 x $15) additional dollars. The total dilution to the common stock is 100,000 shares.

So here's a hypothetical...you buy 10 preferred shares for $33/share, $330. You have the right now to buy 1 share of GNBT at $15. If GNBT goes to $30 per share, you exercise that right and make a $15 profit on that one share ($30 pps - $15 warrant exercise price). You continue to hold the preferred shares, and you are earning 13% annually on their value (.13 x 330 = $42.90 per year).

After 2023, GNBT can buy back the preferred shares for $33/share + any unpaid dividend amount. So for 3 years, you are guaranteed a 13% return and a buyback at what you paid...or, if GNBT does not buy back the preferred shares, you continue to collect the 13% return until they do. If you haven't exercised the warrant within 2 years of your initial purchase of the preferred shares, you lose the ability to buy the one share of GNBT at $15. That would only happen IF GNBT's pps did not exceed $15 in that two year period.

Does anybody see this differently? This is what I'm reading into it, but I can't say definitively that this is what it means.

Generex Biotechnology Corp. (GNBTQ) Stock Research Links

GNBTQ Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

DeepCure Introduces Advanced STAT6 Inhibitor for Inflammation

Updated Category News Views 871

DeepCure's STAT6 Inhibitor Program DeepCure, an innovative therapeutics company harnessing the power of artificial intelligence to unveil groundbreaking therapies for inflammation and immune diseases, has made an exciting announcement. The company recently revealed the development of potent and selective oral small molecule inhibitors designed to target STAT6, a key...

Continue Reading
Microsoft Alumni Network Expands Board for Global Impact

Updated Category News Views 160

Microsoft Alumni Network Enhances Board Leadership The Microsoft Alumni Network, representing over 290,000 former employees from a tech giant, has announced a significant elevation in its board of trustees aimed at strengthening its governance and global outreach. These strategic appointments are not just about filling positions; they signify a dedicated effort to bolster...

Continue Reading
Carl Icahn's Noteworthy Investment in CVR Partners Stock

Updated Category News Views 122

Carl Icahn's Significant Investment in CVR Partners Recently, CARL ICAHN, a notable 10% owner of CVR Partners (UAN), made headlines with a remarkable insider buy. The latest SEC filing disclosed that ICAHN purchased 4,897 shares of CVR Partners, amounting to an investment of $367,016. The timing of this insider transaction, taking place just before a notable decline in...

Continue Reading
Capriotti's Expands with New Kapolei Location for Food Lovers

Updated Category News Views 140

Capriotti's Opens a New Location in Kapolei Award-winning sandwich chain Capriotti's Sandwich Shop is excited to announce the grand opening of its second location in Kapolei. Known for its delicious, hand-crafted cheesesteaks and signature subs, the opening marks a significant milestone for this beloved restaurant. Meet Soojung Heu: The Visionary Behind Capriotti's in...

Continue Reading
Stifel Financial Highlights Strong April 2025 Operating Results

Updated Category News Views 134

Stifel Financial Sees Growth in April 2025 ST. LOUIS, May 22, 2025 – Stifel Financial Corp. (NYSE: SF) recently released its operating results for April 2025, focusing on key performance metrics to inform investors. It's essential to note that while this data is promising, it does not directly correlate to earnings. Total Client Assets on the Rise Ronald J. Kruszewski,...

Continue Reading